Skip to main content

DESARROLLO DE VACUNAS DIVA UNIVERSALES FRENTE AL VIRUS DE LA LENGUA AZUL BASADAS EN RESPUESTA INMUNE CELULAR INDUCIDA POR LAS PROTEINAS NO ESTRUCTURALES DEL VIRUS CONSERVADAS

AGL2017-82570-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA - CSIC

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus

  • Utrilla-Trigo, S.
  • Jiménez-Cabello, L.
  • Alonso-Ravelo, R.
  • Calvo Pinilla, Eva María
  • Marín-López, A.
  • Moreno, Sandra
  • Lorenzo, Gema
  • Benavides, Julio
  • Gilbert, S.
  • Nogales, Aitor
  • Ortego, Javier
20 páginas, 8 figuras., The sequence of non-structural protein NS1 of bluetongue virus (BTV), which contains immunodominant CD8+ T cell epitopes, is highly conserved among BTV serotypes, and has therefore become a major tool in the development of a universal BTV vaccine. In this work, we have engineered multiserotype BTV vaccine candidates based on recombinant chimpanzee adenovirus (ChAdOx1) and modified vaccinia virus Ankara (MVA) vectors expressing the NS1 protein of BTV-4 or its truncated form NS1-Nt. A single dose of ChAdOx1-NS1 or ChAdOx1-NS1-Nt induced a moderate CD8+ T cell response and protected IFNAR(-/-) mice against a lethal dose of BTV-4/MOR09, a reassortant strain between BTV-1 and BTV-4, although the animals showed low viremia after infection. Furthermore, IFNAR(-/-) mice immunized with a single dose of ChAdOx1-NS1 were protected after challenge with a lethal dose of BTV-8 in absence of viremia nor clinical signs. Additionally, the heterologous prime-boost ChAdOx1/MVA expressing NS1 or NS1-Nt elicited a robust NS1 specific CD8+ T cell response and protected the animals against BTV-4/MOR09 even 16 weeks after immunization, with undetectable levels of viremia at any time after challenge. Subsequently, the best immunization strategy based on ChAdOx1/MVA-NS1 was assayed in sheep. Non-immunized animals presented fever and viremia levels up to 10<sup>4</sup> PFU/mL after infection. In contrast, although viremia was detected in immunized sheep, the level of virus in blood was 100 times lower than in non-immunized animals in absence of clinical signs., This work was supported by grants AGL2017-82570-R from the Spanish Ministry of Science and EU Horizon 2020 Program (European Comission Grant Agreement NO.727393-PALE-Blu). SUT was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SGIT-201).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

AGL2017-82570-RReverse genetics approaches for the development of new vaccines against influenza A virus infections

  • Martínez-Sobrido, Luis
  • DeDiego, Marta L.
  • Nogales, Aitor
Influenza A viruses (IAVs) represent a serious concern globally because they are capable of rapid spread and cause severe disease in humans and other animals. The development and implementation of plasmid-based reverse genetics approaches have allowed the manipulation and recovery of recombinant IAVs from complementary DNA copies of the viral genome. Furthermore, IAV reverse genetics have provided researchers an efficient and powerful platform to introduce specific changes in the viral genome with the final goal of studying IAV biology, designing more effective vaccine strategies, and to reduce the rates of incidence and mortality associated with viral infections. In this review, we briefly discuss IAV reverse genetics and their applications to prevent IAV infections., Influenza research in LM-S laboratory has been partially funded by the New York Influenza Center of Excellence (NYICE, NIH 272201400005C), a member of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract No. HHSN272201400005C (NYICE), the NIH/NIAID 1R01AI145332, and the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP) grant W81XWH-18-1-0460. Research in M.L.D laboratory was supported with funds from Comunidad de Madrid, Spain, reference 2017-T1/BMD-5155 and the Spanish Ministry of Science, Innovation and Universities (RTI-2018-094213-A-I00). Research in A.N laboratory was partially funded with the ‘Ramon y Cajal’ Fellowship RYC-2017 from Spanish Ministry of Economy, Industry and Competitiveness and the Spanish Ministry of Science, Innovation and Universities (AGL2017-82570-R).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The combined expression of the nonstructural protein NS1 and the N-terminal half of NS2 (NS21-180) by ChAdOx1 and MVA confers protection against clinical disease in sheep upon bluetongue virus challenge

  • Utrilla-Trigo, S.
  • Jiménez-Cabello, L.
  • Calvo Pinilla, Eva María
  • Marín-López, A.
  • Lorenzo, Gema
  • Sánchez-Cordón, Pedro J.
  • Moreno, Sandra
  • Benavides, Julio
  • Gilbert, S.
  • Nogales, Aitor
  • Ortego, Javier
26 páginas, 2 tablas, 10 figuras., Bluetongue, caused by bluetongue virus (BTV), is a widespread arthropod-borne disease of ruminants that entails a recurrent threat to the primary sector of developed and developing countries. In this work, we report modified vaccinia virus Ankara (MVA) and ChAdOx1-vectored vaccines designed to simultaneously express the immunogenic NS1 protein and/or NS2-Nt, the N-terminal half of protein NS2 (NS21-180). A single dose of MVA or ChAdOx1 expressing NS1-NS2-Nt improved the protection conferred by NS1 alone in IFNAR(-/-) mice. Moreover, mice immunized with ChAdOx1/MVA-NS1, ChAdOx1/MVA-NS2-Nt, or ChAdOx1/MVA-NS1-NS2-Nt developed strong cytotoxic CD81 T-cell responses against NS1, NS2-Nt, or both proteins and were fully protected against a lethal infection with BTV serotypes 1, 4, and 8. Furthermore, although a single immunization with ChAdOx1-NS1-NS2-Nt partially protected sheep against BTV-4, the administration of a booster dose of MVA-NS1- NS2-Nt promoted a faster viral clearance, reduction of the period and level of viremia and also protected from the pathology produced by BTV infection. IMPORTANCE Current BTV vaccines are effective but they do not allow to distinguish between vaccinated and infected animals (DIVA strategy) and are serotype specific. In this work we have develop a DIVA multiserotype vaccination strategy based on adenoviral (ChAdOx1) and MVA vaccine vectors, the most widely used in current phase I and II clinical trials, and the conserved nonstructural BTV proteins NS1 and NS2. This immunization strategy solves the major drawbacks of the current marketed vaccines., This work was supported by grants AGL2017-82570-R and PID2020-112992RR-I00 from the Spanish Ministry of Science and by the EU Horizon 2020 Program (European Commission grant agreement no. 727393-PALE-Blu). S.U.T. was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SGIT2018). We declare no competing interests. J.O. conceived the study. S.U.T. and L.J.C. wrote the manuscript with contributions from J.O. and inputs from all other authors. S.U.T., L.J.C., S.G., and A.M.L. designed and developed all the vaccines used in this work. S.U.T., L.J.C., E.C.P., G.L., and S.M. conducted mice experiments and cytometric analysis. J.B. and P.S.C. conducted sheep immunizations, postmortem studies, and histopathological analysis. S.U.T. and L.J.C. analyzed antibodies, viremias, and hematological parameters. A.N. helped revising the article, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Viral Vector Vaccines against Bluetongue Virus

  • Jiménez-Cabello, L.
  • Utrilla-Trigo, S.
  • Calvo Pinilla, Eva María
  • Moreno, Sandra
  • Nogales, Aitor
  • Ortego, Javier
  • Marín-López, A.
19 Pág. Centro de Investigación en Sanidad Animal (CISA), 9, Issue 1, Pages 1 - 21January 2021, Bluetongue virus (BTV), the prototype member of the genus Orbivirus (family Reoviridae), is the causative agent of an important livestock disease, bluetongue (BT), which is transmitted via biting midges of the genus Culicoides. To date, up to 29 serotypes of BTV have been described, which are classified as classical (BTV 1-24) or atypical (serotypes 25-27), and its distribution has been expanding since 1998, with important outbreaks in the Mediterranean Basin and devastating incursions in Northern and Western Europe. Classical vaccine approaches, such as live-attenuated and inactivated vaccines, have been used as prophylactic measures to control BT through the years. However, these vaccine approaches fail to address important matters like vaccine safety profile, effectiveness, induction of a cross-protective immune response among serotypes, and implementation of a DIVA (differentiation of infected from vaccinated animals) strategy. In this context, a wide range of recombinant vaccine prototypes against BTV, ranging from subunit vaccines to recombinant viral vector vaccines, have been investigated. This article offers a comprehensive outline of the live viral vectors used against BTV., This work was supported by grants AGL2017-82570-R from the Spanish Ministry of Science and the EU Horizon 2020 Program (European Commission Grant Agreement No. 727393-PALE-Blu). S.U.-T. was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SGIT 201). A.N. is supported by a MINECO “Ramon y Cajal” Incorporación grant (RYC-2017)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge

  • Moreno, Sandra
  • Calvo Pinilla, Eva María
  • Devignot, S.
  • Weber, Friedemann
  • Ortego, Javier
  • Brun Torres, Alejandro
25 Pág., Many ruminant diseases of viral aetiology can be effectively prevented using appropriate vaccination measures. For diseases such as Rift Valley fever (RVF) the long inter-epizootic periods make routine vaccination programs unfeasible. Coupling RVF prophylaxis with seasonal vaccination programmes by means of multivalent vaccine platforms would help to reduce the risk of new RVF outbreaks., AB is supported by grants AGL2014-57430R and AGL2017-83226R from the Spanish Ministry of Science, and grant S2018/BAA 4370 from Comunidad de Madrid R&D in Technologies Program. JO is supported by grants AGL2014-57430R and AGL2017-82570R from the Spanish Ministry of Science and Innovation and European Union’s Horizon 2020 research and innovation program under grant proposal 727393-2. SMF is a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Science and innovation. FW is supported by the CCHF Vaccine consortium that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 732732, and by the Swedish Research Council(Vetenskapsrådet, VR) section Research Environment, Infection Biology (contract number 2018-05766). The funding sources had no involvement in the study design nor in the writing of the report and the decision to submit the article for publication, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design

  • Calvo Pinilla, Eva María
  • Marín-López, A.
  • Utrilla-Trigo, S.
  • Jiménez-Cabello, L.
  • Ortego, Javier
9 Pág., African horse sickness (AHS) is a devastating disease caused by African horse sickness virus (AHSV) and transmitted by arthropods between its equine hosts. AHSV is endemic in sub-Saharan Africa, where polyvalent live attenuated vaccine is in use even though it is associated with safety risks. This review article summarizes and compares new strategies to generate safe and effective AHSV vaccines based on protein, virus like particles, viral vectors and reverse genetics technology. Manipulating the AHSV genome to generate synthetic viruses by means of reverse genetic systems has led to the generation of potential safe vaccine candidates that are under investigation., This work was supported by the Spanish Ministry of Science ( AGL2017-82570-R ) and EU Horizon 2020 Program (NO. 727393-PALE-Blu ). Sergio Utrilla-Trigo was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria , Centro de Investigación en Sanidad Animal (program FPI-SGIT-2018)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara

  • Marín-López, A.
  • Barreiro-Piñeiro, Natalia
  • Utrilla-Trigo, S.
  • Barriales, Diego
  • Benavente, Javier
  • Nogales, Aitor
  • Martínez-Costas, José Manuel
  • Ortego, Javier
  • Calvo Pinilla, Eva María
8 Pág., African horse sickness virus (AHSV) is an insect-borne pathogen that causes acute disease in horses and other equids. In an effort to improve the safety of currently available vaccines and to acquire new knowledge about the determinants of AHSV immunogenicity, new generation vaccines are being developed. In this work we have generated and tested a novel immunization approach comprised of nonstructural protein 1 (NS1) of AHSV serotype 4 (AHSV-4) incorporated into avian reovirus muNS protein microspheres (MS-NS1) and/or expressed using recombinant modified vaccinia virus Ankara vector (MVA-NS1). The protection conferred against AHSV by a homologous MS-NS1 or heterologous MS-NS1 and MVA-NS1 prime/boost was evaluated in IFNAR (-/-) mice. Our results indicate that immunization based on MS-NS1 and MVA-NS1 afforded complete protection against the infection with homologous AHSV-4. Moreover, priming with MS-NS1 and boost vaccination with MVA-NS1 (MS-MVA-NS1) triggered NS1 specific cytotoxic CD8 + T cells and prevented AHSV disease in IFNAR (-/-) mice after challenge with heterologous serotype AHSV-9. Cross-protective immune responses are highly important since AHS can be caused by nine different serotypes, which means that a universal polyvalent vaccination would need to induce protective immunity against all serotypes., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades, Spain (AGL-2014-57430-R, AGL2017-82570-R and BFU2013-43513-R). The Xunta de Galicia [Centro singular de investigación de Galicia accreditation 2016-2019 (ED431G/09) and ED431B 2018/04], and the European Regional Development Fund (ERDF) are gratefully acknowledged. We thank Rebeca Menaya for excellent technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor

  • Marín-López, A.
  • Calvo Pinilla, Eva María
  • Moreno, Sandra
  • Utrilla-Trigo, S.
  • Nogales, Aitor
  • Brun Torres, Alejandro
  • Fikrig, Erol
  • Ortego, Javier
25 Pág., Arboviruses are arthropod-borne viruses that exhibit worldwide distribution and are a constant threat, not only for public health but also for wildlife, domestic animals, and even plants. To study disease pathogenesis and to develop efficient and safe therapies, the use of an appropriate animal model is a critical concern. Adult mice with gene knockouts of the interferon α/β (IFN-α/β) receptor (IFNAR(-/-)) have been described as a model of arbovirus infections. Studies with the natural hosts of these viruses are limited by financial and ethical issues, and in some cases, the need to have facilities with a biosafety level 3 with sufficient space to accommodate large animals. Moreover, the number of animals in the experiments must provide results with statistical significance. Recent advances in animal models in the last decade among other gaps in knowledge have contributed to the better understanding of arbovirus infections. A tremendous advantage of the IFNAR(-/-) mouse model is the availability of a wide variety of reagents that can be used to study many aspects of the immune response to the virus. Although extrapolation of findings in mice to natural hosts must be done with care due to differences in the biology between mouse and humans, experimental infections of IFNAR(-/-) mice with several studied arboviruses closely mimics hallmarks of these viruses in their natural host. Therefore, IFNAR(-/-) mice are a good model to facilitate studies on arbovirus transmission, pathogenesis, virulence, and the protective efficacy of new vaccines. In this review article, the most important arboviruses that have been studied using the IFNAR(-/-) mouse model will be reviewed., This manuscript was supported by the Spanish MCIU grants AGL2017-82570-R (to Javier Ortego) and AGL-2017-83226-R (to Alejandro Brun), the EU Horizon 2020 Program (European Commission Grant Agreement NO.727393-PALE-Blu (to Javier Ortego), and by NIH grants AI127865 and AI08992 (to Erol Fikrig)., Peer reviewed